7 results on '"Nagvekar, Vasant"'
Search Results
2. Current Perspectives on Treatment of Gram-Positive Infections in India: What Is the Way Forward?
- Author
-
Kulkarni, Atul P., Nagvekar, Vasant C., Veeraraghavan, Balaji, Warrier, Anup R., TS, Deepak, Ahdal, Jaishid, and Jain, Rishi
- Subjects
- *
MULTIDRUG resistance in bacteria , *METHICILLIN-resistant staphylococcus aureus , *ANTI-infective agents , *BIOCHEMICAL mechanism of action ,INFECTION treatment - Abstract
The emerging antimicrobial resistance leading to gram-positive infections (GPIs) is one of the major public health threats worldwide. GPIs caused by multidrug resistant bacteria can result in increased morbidity and mortality rates along with escalated treatment cost and hospitalisation stay. In India, GPIs, particularly methicillin-resistant Staphylococcus aureus (MRSA) prevalence among invasive S. aureus isolates, have been reported to increase exponentially from 29% in 2009 to 47% in 2014. Apart from MRSA, rising prevalence of vancomycin-resistant enterococci (VRE), which ranges from 1 to 9% in India, has raised concerns. Moreover, the overall mortality rate among patients with multidrug resistant GPIs in India is reported to be 10.8% and in ICU settings, the mortality rate is as high as 16%. Another challenge is the spectrum of adverse effects related to the safety and tolerability profile of the currently available drugs used against GPIs which further makes the management and treatment of these multidrug resistant organisms a complex task. Judicious prescription of antimicrobial agents, implementation of antibiotic stewardship programmes, and antibiotic policies in hospitals are essential to reduce the problem of drug-resistant infections in India. The most important step is development of newer antimicrobial agents with novel mechanisms of action and favourable pharmacokinetic profile. This review provides a synopsis about the current burden, treatment options, and the challenges faced by the clinicians in the management of GPIs such as MRSA, Quinolone-resistant Staphylococcus, VRE, and drug-resistant pneumococcus in India. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Salmonella Typhi acquires diverse plasmids from other Enterobacteriaceae to develop cephalosporin resistance.
- Author
-
Jacob, Jobin John, Pragasam, Agila Kumari, Vasudevan, Karthick, Veeraraghavan, Balaji, Kang, Gagandeep, John, Jacob, Nagvekar, Vasant, and Mutreja, Ankur
- Subjects
- *
SALMONELLA typhi , *CEPHALOSPORINS , *ENTEROBACTERIACEAE , *TYPHOID fever , *GENOMICS , *CEFTRIAXONE - Abstract
Recent reports have established the emergence and dissemination of extensively drug resistant (XDR) H58 Salmonella Typhi clone in Pakistan. In India where typhoid fever is endemic, only sporadic cases of ceftriaxone resistant S. Typhi are reported. This study aimed at elucidating the phylogenetic evolutionary framework of ceftriaxone resistant S. Typhi isolates from India to predict their potential dissemination. Five ceftriaxone resistant S. Typhi isolates from three tertiary care hospitals in India were sequenced on an Ion Torrent Personal Genome Machine (PGM). A core genome single-nucleotide-polymorphism (SNP) based phylogeny of the isolates in comparison to the global collection of MDR and XDR S. Typhi isolates was built. Two of five isolates were additionally sequenced using Oxford Nanopore MinION to completely characterize the plasmid and understand its transmission dynamics within Enterobacteriaceae. Comparative genomic analysis and detailed plasmid characterization indicate that while in Pakistan (4.3.1 lineage I) the XDR trait is associated with bla CTX-M-15 gene on IncY plasmid, in India (4.3.1 lineage II), the ceftriaxone resistance is due to short term persistence of resistance plasmids such as IncX3 (bla SHV-12) or IncN (bla T EM-1B + bla DHA-1). Considering the selection pressure exerted by the extensive use of ceftriaxone in India, there are potential risks for the occurrence of plasmid transmission events in the predominant H58 lineages. Therefore, continuous monitoring of S. Typhi lineages carrying plasmid-mediated cephalosporin resistant genes is vital not just for India but also globally. • S. Typhi to develop cephalosporin resistance by acquiring diverse plasmids from other Enterobacteriaceae. • Independent acquisition of drug-resistant plasmids such as IncX3 and IncN with genes encoding beta-lactamases in H58 lineage II of S. Typhi. • A short-term persistence of drug-resistant plasmids in H58 lineage II can be the reason for the sporadic cases cephalosporin resistant S. Typhi in India. • Plasmid acquisition and maintenance of cephalosporin resistant S. Typhi appears to be specific to the phylogenetic lineage. • Critical strategies in monitoring and control of cephalosporin resistant S. Typhi is needed to tackle further public health crisis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Risk factors, mortality, and predictors of survival in COVID-19-associated pulmonary mucormycosis: a multicentre retrospective study from India.
- Author
-
Muthu V, Agarwal R, Rudramurthy SM, Thangaraju D, Shevkani MR, Patel AK, Shastri PS, Tayade A, Bhandari S, Gella V, Savio J, Madan S, Hallur V, Maturu VN, Srinivasan A, Sethuraman N, Singh Sibia RP, Pujari S, Mehta R, Singhal T, Saxena P, Gupta V, Nagvekar V, Prayag P, Patel D, Xess I, Savaj P, Sehgal IS, Panda N, Rajagopal GD, Parwani RS, Patel K, Deshmukh A, Vyas A, Gandra RR, Sistla SK, Padaki PA, Ramar D, Sarkar S, Rachagulla B, Vallandaramam P, Premachandran KP, Pawar S, Gugale P, Hosamani P, Dutt SN, Nair S, Kalpakkam H, Badhwar S, Kompella KK, Singla N, Navlakhe M, Prayag A, Singh G, Dhakecha P, and Chakrabarti A
- Subjects
- Humans, Male, Retrospective Studies, Cohort Studies, Glucocorticoids, Risk Factors, India epidemiology, Hypoxia complications, Mucormycosis complications, Mucormycosis epidemiology, Coinfection, COVID-19 complications, COVID-19 therapy, Aspergillosis
- Abstract
Objectives: To compare COVID-19-associated pulmonary mucormycosis (CAPM) with COVID-19-associated rhino-orbital mucormycosis (CAROM), ascertain factors associated with CAPM among patients with COVID-19, and identify factors associated with 12-week mortality in CAPM., Methods: We performed a retrospective multicentre cohort study. All study participants had COVID-19. We enrolled CAPM, CAROM, and COVID-19 subjects without mucormycosis (controls; age-matched). We collected information on demography, predisposing factors, and details of COVID-19 illness. Univariable analysis was used to compare CAPM and CAROM. We used multivariable logistic regression to evaluate factors associated with CAPM (with hypoxemia during COVID-19 as the primary exposure) and at 12-week mortality., Results: We included 1724 cases (CAPM [n = 122], CAROM [n = 1602]) and 3911 controls. Male sex, renal transplantation, multimorbidity, neutrophil-lymphocyte ratio, intensive care admission, and cumulative glucocorticoid dose for COVID-19 were significantly higher in CAPM than in CAROM. On multivariable analysis, COVID-19-related hypoxemia (aOR, 2.384; 95% CI, 1.209-4.700), male sex, rural residence, diabetes mellitus, serum C-reactive protein, glucocorticoid, and zinc use during COVID-19 were independently associated with CAPM. CAPM reported a higher 12-week mortality than CAROM (56 of the 107 [52.3%] vs. 413 of the 1356 [30.5%]; p = 0.0001). Hypoxemia during COVID-19 (aOR [95% CI], 3.70 [1.34-10.25]) and Aspergillus co-infection (aOR [95% CI], 5.40 [1.23-23.64]) were independently associated with mortality in CAPM, whereas surgery was associated with better survival., Discussion: CAPM is a distinct entity with a higher mortality than CAROM. Hypoxemia during COVID-19 illness is associated with CAPM. COVID-19 hypoxemia and Aspergillus co-infection were associated with higher mortality in CAPM., (Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. Multicenter Case-Control Study of COVID-19-Associated Mucormycosis Outbreak, India.
- Author
-
Muthu V, Agarwal R, Rudramurthy SM, Thangaraju D, Shevkani MR, Patel AK, Shastri PS, Tayade A, Bhandari S, Gella V, Savio J, Madan S, Hallur VK, Maturu VN, Srinivasan A, Sethuraman N, Sibia RPS, Pujari S, Mehta R, Singhal T, Saxena P, Gupta V, Nagvekar V, Prayag P, Patel D, Xess I, Savaj P, Panda N, Rajagopal GD, Parwani RS, Patel K, Deshmukh A, Vyas A, Sistla SK, Padaki PA, Ramar D, Sarkar S, Rachagulla B, Vallandaramam P, Premachandran KP, Pawar S, Gugale P, Hosamani P, Dutt SN, Nair S, Kalpakkam H, Badhwar S, Kompella KK, Singla N, Navlakhe M, Prayag A, Singh G, Dhakecha P, and Chakrabarti A
- Subjects
- Humans, Case-Control Studies, India epidemiology, Multicenter Studies as Topic, Mucormycosis diagnosis, Mucormycosis epidemiology, COVID-19 epidemiology, Mucorales
- Published
- 2023
- Full Text
- View/download PDF
6. Prevalence of multidrug-resistant Gram-negative bacteria cases at admission in a multispeciality hospital.
- Author
-
Nagvekar V, Sawant S, and Amey S
- Subjects
- Cross-Sectional Studies, Humans, India epidemiology, Prevalence, Retrospective Studies, Gram-Negative Bacteria, Gram-Negative Bacterial Infections epidemiology
- Abstract
Objectives: The prevalence of drug-resistant cases is increasing globally. The present study aimed to investigate the prevalence of cases of blood culture positive for multidrug-resistant Gram-negative bacteria (MDR-GNB) at the time of admission, i.e. within 24h of admission to hospital from primary or secondary care centres., Methods: This record-based retrospective cross-sectional study was designed to analyze MDR-GNB-positive cases at Fortis Hospital, Mumbai, India. Fortis Hospital is a 500-bed referral tertiary care centre. An increase of MDR-GNB was seen from January 2012 to June 2014 in the hospital. A retrospective analysis of blood culture GNB-positive samples was performed to evaluate MDR-GNB-positive cases at admission., Results: The total number of positive blood cultures in January to December 2012, January to December 2013 and January to June 2014 were 221, 236 and 116, respectively, with 77.83%, 79.66% and 69.83% GNB-positive. Total MDR-GNB-positive cases were 26.16%, 32.98% and 33.33%, respectively, and amongst these MDR-GNB, 22%, 32% and 37% where positive at time of admission to the hospital. The MDR-GNB were Escherichia coli, Klebsiella, Acinetobacter, Pseudomonas and Enterobacter., Conclusion: MDR-GNB blood cultures positive at admission rose from January 2012 to June 2014 and hence there is an urgent need for possible contact isolation of all patients coming from primary and secondary to tertiary health care centres which should be made compulsory until screening rules out MDR-GNB to prevent spread of MDR organisms in the hospital., (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
7. Towards adult vaccination in India: a narrative literature review.
- Author
-
Dash R, Agrawal A, Nagvekar V, Lele J, Di Pasquale A, Kolhapure S, and Parikh R
- Subjects
- India epidemiology, Vaccination, Vaccination Coverage, Immunization Programs, Vaccines
- Abstract
Despite vast improvements in childhood vaccination coverage in India, adult vaccination coverage is negligible. Our aim was, therefore, to create awareness about the importance of adult immunization. Although the true burden of vaccine-preventable diseases (VPDs) among Indian adults is unknown, adults are particularly vulnerable during outbreaks, due to a lack of immunization, waning immunity, age-related factors (e.g. chronic conditions and immunosenescence), and epidemiological shift. There are no national adult immunization guidelines in India, and although several medical societies have published adult immunization guidelines, these vary, making it unclear who should receive which vaccines (based on age, underlying conditions, etc.). Other barriers to adult immunization include vaccine hesitancy, missed opportunities, and cost. Steps to improve adult vaccination could include: adoption of national guidelines, education of healthcare providers and the public, and promotion of life-course immunization. Improving adult vaccine coverage could help reduce the burden of VPDs, particularly among older adults.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.